Potentially, the hypothesized “extension” of the window of opportunity does not hold for ACPA-positive RA patients since these have a longer pre-arthritis phase [35] and, possibly, disease processes have fully matured at the time of diagnosis and initiation of treatment. This evidence concerns the gene PRTN3 and arthritic joint disease.